140 related articles for article (PubMed ID: 34238629)
1. Mobile low-threshold buprenorphine integrated with infectious disease services.
Rosecrans A; Harris R; Saxton RE; Cotterell M; Zoltick M; Willman C; Blackwell I; Bell J; Hayes D; Weir B; Sherman S; Lucas GM; Greenbaum A; Page KR
J Subst Abuse Treat; 2022 Feb; 133():108553. PubMed ID: 34238629
[TBL] [Abstract][Full Text] [Related]
2. Integrated care van delivery of evidence-based services for people who inject drugs: A cluster-randomized trial.
Page KR; Weir BW; Zook K; Rosecrans A; Harris R; Grieb SM; Falade-Nwulia O; Landry M; Escobar W; Ramirez MP; Saxton RE; Clarke WA; Sherman SG; Lucas GM
Addiction; 2024 Jul; 119(7):1276-1288. PubMed ID: 38561602
[TBL] [Abstract][Full Text] [Related]
3. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.
Krawczyk N; Buresh M; Gordon MS; Blue TR; Fingerhood MI; Agus D
J Subst Abuse Treat; 2019 Aug; 103():1-8. PubMed ID: 31229187
[TBL] [Abstract][Full Text] [Related]
4. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.
Weiss L; Netherland J; Egan JE; Flanigan TP; Fiellin DA; Finkelstein R; Altice FL;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S68-75. PubMed ID: 21317597
[TBL] [Abstract][Full Text] [Related]
5. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.
Fiellin DA; Weiss L; Botsko M; Egan JE; Altice FL; Bazerman LB; Chaudhry A; Cunningham CO; Gourevitch MN; Lum PJ; Sullivan LE; Schottenfeld RS; O'Connor PG;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(0 1):S33-8. PubMed ID: 21317592
[TBL] [Abstract][Full Text] [Related]
6. A mobile addiction service for community-based overdose prevention.
Pepin MD; Joseph JK; Chapman BP; McAuliffe C; O'Donnell LK; Marano RL; Carreiro SP; Garcia EJ; Silk H; Babu KM
Front Public Health; 2023; 11():1154813. PubMed ID: 37538275
[TBL] [Abstract][Full Text] [Related]
7. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
Altice FL; Bruce RD; Lucas GM; Lum PJ; Korthuis PT; Flanigan TP; Cunningham CO; Sullivan LE; Vergara-Rodriguez P; Fiellin DA; Cajina A; Botsko M; Nandi V; Gourevitch MN; Finkelstein R;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S22-32. PubMed ID: 21317590
[TBL] [Abstract][Full Text] [Related]
8. Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program.
Harris R; Rosecrans A; Zoltick M; Willman C; Saxton R; Cotterell M; Bell J; Blackwell I; Page KR
Drug Alcohol Depend; 2022 Jan; 230():109187. PubMed ID: 34890927
[TBL] [Abstract][Full Text] [Related]
9. Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment.
Hill K; Nussdorf L; Mount JD; Silk R; Gross C; Sternberg D; Bijole P; Jones M; Kier R; Mccullough D; Mathur P; Kottilil S; Masur H; Kattakuzhy S; Rosenthal ES
J Addict Med; 2022 Jan-Feb 01; 16(1):10-17. PubMed ID: 33560694
[TBL] [Abstract][Full Text] [Related]
10. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone.
Sullivan LE; Botsko M; Cunningham CO; O'Connor PG; Hersh D; Mitty J; Lum PJ; Schottenfeld RS; Fiellin DA;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S54-61. PubMed ID: 21317595
[TBL] [Abstract][Full Text] [Related]
11. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
Sadek J; Saunders J
BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
[TBL] [Abstract][Full Text] [Related]
12. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.
Chaudhry AA; Botsko M; Weiss L; Egan JE; Mitty J; Estrada B; Lucas GM; Woodson T; Flanigan TP; Fiellin DA;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S14-21. PubMed ID: 21317589
[TBL] [Abstract][Full Text] [Related]
13. The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment.
Weiss L; Egan JE; Botsko M; Netherland J; Fiellin DA; Finkelstein R
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S7-13. PubMed ID: 21317598
[TBL] [Abstract][Full Text] [Related]
14. Effect of Inpatient Medication-Assisted Therapy on Against-Medical-Advice Discharge and Readmission Rates.
Wang SJ; Wade E; Towle J; Hachey T; Rioux J; Samuels O; Bonner C; Kirkpatrick C; O'Loughlin S; Foster K
Am J Med; 2020 Nov; 133(11):1343-1349. PubMed ID: 32445720
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy?
Taylor LE; Maynard MA; Friedmann PD; Macleod CJ; Rich JD; Flanigan TP; Sylvestre DL
J Addict Med; 2012 Sep; 6(3):179-85. PubMed ID: 22614935
[TBL] [Abstract][Full Text] [Related]
16. Integration of buprenorphine for substance-abuse treatment by HIV care providers.
Friedland G; Vlahov D
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S1-2. PubMed ID: 21317588
[No Abstract] [Full Text] [Related]
17. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
18. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
Parish WJ; Mark TL; Zarkin GA; Weber E
Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
[TBL] [Abstract][Full Text] [Related]
19. Adherence to buprenorphine treatment guidelines among individuals with an opioid use disorder who have private insurance.
Mark TL; Hinde JM; Zarkin GA; Parish W; Kluckman M
J Subst Abuse Treat; 2020 Sep; 116():108062. PubMed ID: 32741503
[TBL] [Abstract][Full Text] [Related]
20. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
